Clinical Progress Ocular Therapeutix is advancing AXPAXLI (OTX-TKI) in Phase 3 for wet AMD with potential applicability to NPDR and DME, signaling opportunities for clinical partnerships, CRO engagements, and late-stage study collaborations.

Commercial Leadership New Global Chief Commercial Officer appointed in 2026, indicating a strategic push for commercial readiness and U.S. and international market expansion plans, inviting conversations on market access, payer strategies, and field organization design.

Strategic Partnerships Active presence at major retina events and investor briefings plus a history of collaborations suggests opportunities to pursue co-development, licensing, or joint reimbursement initiatives with ophthalmology-focused partners.

Financial Capacity Substantial funding and a revenue range in the tens of millions position the company to invest in manufacturing scale, patient access programs, and real-world evidence studies to support product adoption.

Competitive Landscape Industry litigation activity with EyePoint indicates a high-stakes competitive environment; engaging proactively on differentiated delivery, safety profiles, and clinical outcomes can help position as a preferred partner or vendor in retina therapeutics.